The short version of certificate of analysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-15. Anything still debated is marked as such rather than presented as settled.
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
| Property | Value | Notes |
|---|---|---|
| 分子类别 | 合成多肽 | 含非天然氨基酸与脂肪酸侧链 |
| 分子量 | 约 4.7 kDa | 多肽量级，精确值随计法而异 |
| 外观 | 白色至类白色冻干粉 | 常见冻干形态，供复溶使用 |
| 溶解性 | 易溶于水 | 复溶后为澄清至微乳光液体 |
| 常见同义词 | LY3437943 | 开发阶段使用的代号 |
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
Boiled potatoes. Take a thoroughly washed potato and boil it in water; when it is ready, it needs to be cleaned, cut, greased with butter and pepper. (French: Tartoufle boullye. Prennez tartoufle bien lauee, & la mettez boullir dedans eau, eſtant cuite il la faut peler & coupper par tranches, beurre fondu par deſſus, & poiure.)
Molecular cloning is the laboratory process used to produce recombinant DNA. It is one of two most widely used methods, along with polymerase chain reaction (PCR), used to direct the replication of any specific DNA sequence chosen by the experimentalist. There are two fundamental differences between the methods. One is that molecular cloning involves replication of the DNA within a living cell, while PCR replicates DNA in the test tube, free of living cells. The other difference is that cloning involves cutting and pasting DNA sequences, while PCR amplifies by copying an existing sequence. Formation of recombinant DNA requires a cloning vector, a DNA molecule that replicates within a living cell. Vectors are generally derived from plasmids or viruses, and represent relatively small segments of DNA that contain necessary genetic signals for replication, as well as additional elements for convenience in inserting foreign DNA, identifying cells that contain recombinant DNA, and, where appropriate, expressing the foreign DNA. The choice of vector for molecular cloning depends on the choice of host organism, the size of the DNA to be cloned, and whether and how the foreign DNA is to be expressed. The DNA segments can be combined by using a variety of methods, such as restriction enzyme/ligase cloning or Gibson assembly.
The advent of parallel MRI resulted in extensive research and development in image reconstruction and RF coil design, as well as in a rapid expansion of the number of receiver channels available on commercial MR systems. Parallel MRI is now used routinely for MRI examinations in a wide range of body areas and clinical or research applications.
Additionally, the relative (and quantitative) success of the shock therapies, despite the considerable risks they posed to patients, also helped to inspire doctors in the field to pioneer ever more drastic forms of medical interventions, including lobotomies. The clinician-historian Joel Braslow argues that from malarial therapy onward to lobotomy, physical psychiatric therapies "spiral closer and closer to the interior of the brain", with this organ increasingly taking "center stage as a source of disease and site of cure". For medical historian Roy Porter, the often violent and invasive psychiatric interventions developed during the 1930s and 1940s are indicative of both the well-intentioned desire of psychiatrists to find some medical means of alleviating the suffering of the vast number of patients then in psychiatric hospitals and also the relative lack of social power of those same patients to resist the increasingly radical and even reckless interventions of asylum doctors. Many doctors, patients, and family members of the period believed that, despite potentially catastrophic consequences, the results of lobotomy were seemingly positive in many instances or were at least deemed as such when measured next to the apparent alternative of long-term institutionalisation. Lobotomy has always been controversial, but for a period of the medical mainstream, it was regarded as a legitimate last-resort remedy for categories of patients who were otherwise regarded as hopeless.
=== Vascular anomalies === A vascular anomaly can be either a vascular tumor or a birthmark, or a vascular malformation. In a tumor such as infantile hemangioma the mass is soft, and easily compressed, and their coloring is due to the dilated anomalous involved veins. They are most commonly found in the head and neck. Venous malformations are the type of vascular malformation that involves the veins. They can often extend deeper from their surface appearance, reaching underlying muscle or bone. In the neck they may extend into the lining of the mouth cavity or into the salivary glands. They are the most common of the vascular malformations. A severe venous malformation can involve the lymph vessels as a lymphaticovenous malformation.
Sources: en.wikipedia.org
A transdermal gel was formulated to address this but plasma concentrations were undetectable. In cats oral tramadol at 6 mg/kg provides equivalent analgesia to intramuscular tramadol at 4 mg/kg. One study comparing tramadol to meperidine found tramadol to be more effective at providing analgesia for cats undergoing ovariohysterectomy. A study looking at treatment of osteoarthritis in geriatric cats found owner-reported improvements but also significant adverse effects. Reported adverse effects of tramadol include: diarrhoea, dysphoria, anorexia, tachycardia, pyrexia, tachypnoea, and increased levels of serotonin leading to agitation. Tramadol has the potential to cause serotonin syndrome when administered alongside serotonin re-uptake inhibitors, monoamine oxidase inhibitors, and tricyclic antidepressants. In horses, tramadol is ineffective by itself. Two studies looking at intravenous tramadol found it provided no thermal or mechanical antinociception, another study looking at oral tramadol for chronic laminitis found it provided minimal analgesia, and another study looking at intraarticular tramadol found it provided no post-operative analgesia following arthroscopy; however, when administered with paracetamol (acetaminophen) tramadol provides short-acting mechanical antinociception and when administered with ketamine oral tramadol provides adequate analgesia for chronic laminitis. Based on this evidence tramadol is not recommended to be provided on its own for analgesia in horses.
CF2ClCO2Na → NaCl + CF2 + CO2 Decarboxylations are an important in the malonic and acetoacetic ester synthesis. The Knoevenagel condensation and they allow keto acids serve as a stabilizing protecting group for carboxylic acid enols. For the free acids, conditions that deprotonate the carboxyl group (possibly protonating the electron-withdrawing group to form a zwitterionic tautomer) accelerate decarboxylation. A strong base is key to ketonization, in which a pair of carboxylic acids combine to the eponymous functional group:
A Taylor cone refers to the cone observed in electrospinning, electrospraying and hydrodynamic spray processes from which a jet of charged particles emanates above a threshold voltage. Aside from electrospray ionization in mass spectrometry, the Taylor cone is important in field-emission electric propulsion (FEEP) and colloid thrusters used in fine control and high efficiency (low power) thrust of spacecraft.
The administration of President Álvaro Uribe (2002–2010) adopted the democratic security policy which included an integrated counter-terrorism and counter-insurgency campaign. The government economic plan also promoted confidence in investors. As part of a controversial peace process, the AUC (right-wing paramilitaries) had ceased to function formally as an organization . In February 2008, millions of Colombians demonstrated against FARC and other outlawed groups. After peace negotiations in Cuba, the Colombian government of President Juan Manuel Santos and the guerrillas of the FARC-EP announced a final agreement to end the conflict. However, a referendum to ratify the deal was unsuccessful. Afterward, the Colombian government and the FARC signed a revised peace deal in November 2016, which the Colombian congress approved. In 2016, President Santos was awarded the Nobel Peace Prize. The Government began a process of attention and comprehensive reparation for victims of conflict. Colombia shows modest progress in the struggle to defend human rights, as expressed by HRW. A Special Jurisdiction of Peace has been created to investigate, clarify, prosecute and punish serious human rights violations and grave breaches of international humanitarian law which occurred during the armed conflict and to satisfy victims' right to justice. During his visit to Colombia, Pope Francis paid tribute to the victims of the conflict.
== Selected publications == Drucker, D. J.; Philippe, J; Mojsov, S; Chick, W. L.; Habener, J. F. (1987). "Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line". Proceedings of the National Academy of Sciences of the United States of America. 84 (10): 3434–8. Bibcode:1987PNAS...84.3434D. doi:10.1073/pnas.84.10.3434. PMC 304885. PMID 3033647. Scrocchi, L.S.; Brown, T.J.; Maclusky, N.; Brubaker, P.L.; Auerbach, A.B.; Joyner, A.L.; Drucker, D.J. (1996). "Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene". Nature Medicine. 2 (11): 1254–1258. doi:10.1038/nm1196-1254. PMID 8898756. Drucker, D.J.; Ehrlich, P.; Asa, S. L.; Brubaker, P.L. (1996). "Induction of intestinal epithelial proliferation by glucagon-like peptide 2". Proc Natl Acad Sci U S A. 93 (15): 7911–7916. Bibcode:1996PNAS...93.7911D. doi:10.1073/pnas.93.15.7911. PMC 38848. PMID 38848. Chen, E.; Drucker, D.J. (1997). "Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard". Journal of Biological Chemistry. 272 (7): 4108–15. doi:10.1074/jbc.272.7.4108. PMID 9020121. Drucker, D.J.; Shi, Q.; Crivici, A.; Sumner-Smith, M.; Tavares, W.; Hill, M.; DeForest, L.; Cooper, S.; Brubaker, P.L. (1997). "Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV". Nature Biotechnology. 93 (15): 7911–6. doi:10.1038/nbt0797-673. PMID 9219272.
Sources: en.wikipedia.org
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。
天然肽类在体内容易被酶解并快速清除。脂肪酸侧链与非天然氨基酸可以延缓清除、降低酶解速率。修饰后的分子因此更适合较长间隔的给药安排。
公开资料主要来自临床阶段的报告与注册平台记录。这些材料提供的是阶段性信息，而非最终结论。完整的安全性与有效性数据仍在积累中。
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.